SAN

73.08

+0.69%↑

SRT3

210.3

-3.49%↓

ORNBV.FI

67.5

-0.13%↓

PHMA

97.05

-0.41%↓

DRW3

84.5

-1.8%↓

SAN

73.08

+0.69%↑

SRT3

210.3

-3.49%↓

ORNBV.FI

67.5

-0.13%↓

PHMA

97.05

-0.41%↓

DRW3

84.5

-1.8%↓

SAN

73.08

+0.69%↑

SRT3

210.3

-3.49%↓

ORNBV.FI

67.5

-0.13%↓

PHMA

97.05

-0.41%↓

DRW3

84.5

-1.8%↓

SAN

73.08

+0.69%↑

SRT3

210.3

-3.49%↓

ORNBV.FI

67.5

-0.13%↓

PHMA

97.05

-0.41%↓

DRW3

84.5

-1.8%↓

SAN

73.08

+0.69%↑

SRT3

210.3

-3.49%↓

ORNBV.FI

67.5

-0.13%↓

PHMA

97.05

-0.41%↓

DRW3

84.5

-1.8%↓

Strona główna・Stock List・Vetoquinol SA

Vetoquinol SA

Open

SectorHealthcare

71.8 -6.87

Buy Sell

Overview

Share price change

24h

Current

Min

71.3

Max

77.1

Key metrics
By Trading Economics
Income	7.2M 32M
Sales	10M 268M
P/E Sector Avg	14.777 51.415
Dividend yield	1.25
Profit margin	12.043
Employees	2,497
EBITDA	252M 301M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+50.68% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	1.25% 2.34%

Market Stats
By TradingEconomics
Market Cap	-86M 849M
Previous open	78.67
Previous close	71.8

News Sentiment

By Acuity

50%

150 / 346 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

72.6 / 75.1 Support & Resistance

Vetoquinol SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 maj 2026, 22:50 UTC

Earnings

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 maj 2026, 22:49 UTC

Earnings

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 maj 2026, 22:32 UTC

Earnings

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 maj 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 maj 2026, 22:57 UTC

Market Talk

Earnings

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 maj 2026, 22:26 UTC

Earnings

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 maj 2026, 22:25 UTC

Earnings

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 maj 2026, 22:25 UTC

Earnings

Aristocrat Leisure Interim Dividend A$0.50/Security

12 maj 2026, 22:24 UTC

Earnings

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 maj 2026, 22:23 UTC

Earnings

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 maj 2026, 22:23 UTC

Earnings

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 maj 2026, 22:19 UTC

Earnings

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 maj 2026, 22:14 UTC

Earnings

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 maj 2026, 22:14 UTC

Earnings

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 maj 2026, 22:13 UTC

Earnings

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 maj 2026, 22:12 UTC

Earnings

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 maj 2026, 22:12 UTC

Earnings

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 maj 2026, 22:11 UTC

Earnings

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 maj 2026, 22:11 UTC

Earnings

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 maj 2026, 22:10 UTC

Earnings

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 maj 2026, 22:09 UTC

Earnings

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 maj 2026, 22:09 UTC

Earnings

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 maj 2026, 22:08 UTC

Earnings

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 maj 2026, 22:07 UTC

Earnings

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 maj 2026, 22:06 UTC

Earnings

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 maj 2026, 22:06 UTC

Earnings

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 maj 2026, 22:05 UTC

Earnings

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 maj 2026, 22:04 UTC

Earnings

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 maj 2026, 22:04 UTC

Earnings

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 maj 2026, 22:04 UTC

Earnings

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer Comparison

Price change

Vetoquinol SA Forecast

Price Target

By TipRanks

50.68% upside

12 Months Forecast

Average 110 EUR 50.68%

High 110 EUR

Low 110 EUR

Based on 1 Wall Street analysts offering 12 month price targets forVetoquinol SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Vetoquinol SA - Dist in the past 3 months.

Technical Score

By Trading Central

72.6 / 75.1Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

150 / 346 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.